"When it comes to children's health, clinical evidence must guide decisions to ensure any medicine given to young Kiwis is proven, safe and effective,"
"The independent Cass Review, commissioned by the UK's NHS, identified considerable uncertainty about the long-term safety and clinical effectiveness of hormone-suppressing treatments for gender dysphoria or incongruence. This wasn't a political review, it was clinical."
"New Zealand's own Ministry of Health reached the same conclusions in November 2024. Its evidence brief found significant limitations in the quality of evidence regarding both benefits and risks when hormone-suppressing treatments are used for the treatment of gender dysphoria or incongruence."
New Zealand will halt new prescriptions of gonadotropin-releasing hormone analogues for treating gender dysphoria in youth from 19 December, while preserving existing prescriptions and allowing clinical exceptions. Exemptions include use for early-onset puberty, endometriosis, prostate cancer, and cases where clinical evidence clearly demonstrates benefit. The government described the move as a precautionary approach, citing the UK Cass Review's identification of uncertainty about long-term safety and clinical effectiveness of hormone-suppressing treatments. New Zealand's Ministry of Health evidence brief in November 2024 reached similar conclusions. Major UK clinical trial results are not expected until 2031.
Read at PinkNews | Latest lesbian, gay, bi and trans news | LGBTQ+ news
Unable to calculate read time
Collection
[
|
...
]